Measles, mumps and rubella vaccine(Merck Sharp & Dohme)(Measles, mumps and rubella vaccine(Merck Sharp & Dohme))

概要

基本信息

药物类型

联合疫苗、减毒活疫苗、预防性疫苗

别名

M-M-RVAXPRO、MMR vaccine、Measles, Mumps, and Rubella Virus Vaccine, Live (Merck & Co)

+ [3]

靶点-

作用机制

免疫刺激剂

治疗领域

感染口颌疾病其他疾病

在研适应症

麻疹腮腺炎风疹

非在研适应症-

原研机构

Merck Sharp & Dohme Corp.

在研机构

Merck Sharp & Dohme BV

Merck & Co., Inc.

非在研机构-

最高研发阶段批准上市

首次获批日期

美国 (1971-04-22),

麻疹腮腺炎风疹

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

39

项与 Measles, mumps and rubella vaccine(Merck Sharp & Dohme) 相关的临床试验

NCT06456788 / Not yet recruitingN/A

Exploring Barriers and Facilitators to Uptake of the MMR Vaccine Among Healthcare Workers at King's College Hospital NHS Foundation Trust

Measles is a highly contagious disease which can result in severe complications in some patients. Healthcare workers have a higher risk of getting measles than the general population because of their increased risk of exposure from patients with measles attending hospitals. Having had measles in the past or at least one dose of the measles, mumps and rubella (MMR) vaccine provides protection (immunity) against measles. UK government guidelines therefore recommend that healthcare workers and non-clinical staff with direct patient contact are fully vaccinated or have other evidence of immunity. Yet, evidence from recent measles outbreaks suggests that some healthcare workers are not immune or do not know if they are immune, with implications for containment efforts, cost and transmission. The purpose of this study is to identify barriers and facilitators to uptake of the MMR vaccine among healthcare workers at King's College Hospital NHS Foundation Trust (KCH). KCH healthcare workers will be eligible to take part in the study if they are aged 18 and over and have direct contact with patients. In addition, the research will focus on four subgroups of healthcare workers at KCH: those who are not immune, those who have not completed the full vaccination schedule, those who don't know their immunity status, those received the vaccine only after joining KCH. The latter may provide insights into facilitators to vaccine uptake. Measles immunity forms part of the occupational health screening at KCH. A series of semi structured interviews lasting approximately 1 hour will explore participants' experiences of the occupational health vaccine screening process and measles vaccine campaigns at KCH; why they are unvaccinated/not fully vaccinated/do not know if they are immune/decided to be vaccinated after joining KCH; and what measures or interventions may help healthcare workers when deciding whether to get the MMR vaccine.

开始日期2024-07-01

申办/合作机构

King's College London

[+1]

PACTR202405741158761 / Suspended临床3期

A Phase III, Multi-Center, Randomized, Observer-Blind, Active Controlled Non-Inferiority Study to Evaluate the Immunogenicity and Safety of Shanghai Institute of Biological Products Co., Ltd.’s Measles, Mumps and Rubella (MMR) Vaccine Compared to a Licensed and WHO Prequalified GSK MMR Vaccine in Healthy African Children, 9- 11 Months of Age.

开始日期2024-06-17

申办/合作机构

上海生物制品研究所有限责任公司

NCT06397768 / Recruiting临床3期

Phase III, Randomized, Single-blind, Placebo-controlled, Multi-center Study to Evaluate Non-interference of Concomitant Administration of Routine Pediatric Vaccines on the Antibody Response of an Investigational Live-attenuated Respiratory Syncytial Virus (RSV) Vaccine in Healthy Infants and Toddlers (CORAL)

This study is a Phase III, randomized, single-blind, placebo-controlled, multi-center study to be conducted in healthy infants and toddlers which will be enrolled at approximately 6 months of age (Cohort 1) and approximately 12 months of age (Cohort 2). The primary objective of the study will be to assess non-inferiority of the RSV infant and toddler (RSVt) vaccine antibody response when administered concomitantly with routine pediatric vaccines at 6 months of age (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine [Vaxelis® or Pentacel® and Recombivax HB®] Prevnar 20®, and RotaTeq®), and 12 months of age (M-M-R II, VARIVAX, and Prevnar 20 or per local country recommendations) compared to when administered non-concomitantly.

开始日期2024-05-13

申办/合作机构

Sanofi Pasteur

100 项与 Measles, mumps and rubella vaccine(Merck Sharp & Dohme) 相关的临床结果

登录后查看更多信息

100 项与 Measles, mumps and rubella vaccine(Merck Sharp & Dohme) 相关的转化医学

登录后查看更多信息

100 项与 Measles, mumps and rubella vaccine(Merck Sharp & Dohme) 相关的专利（医药）

登录后查看更多信息

387

项与 Measles, mumps and rubella vaccine(Merck Sharp & Dohme) 相关的文献（医药）

2024-12-01·Nursing & health sciences

Effects of Simulation on Nursing students' Knowledge and Learning Related to Measles Vaccine and Vaccine Hesitancy: A Mixed Method Study.

Article

作者: Stephen, Tracey ; Yılmaz, Hülya ; Gundermann, Cynthia

Vaccine hesitancy is a persistent, global public health concern that community health nurses are well-positioned to manage. Simulations involving standardized patients are effective experiential learning on managing vaccine hesitancy for other allied health disciplines. A pretest-posttest design, with a mixed-methods, one-group, quasi-experimental approach, was used to examine the effectiveness of a simulation on nursing students' knowledge of measles, mumps, and rubella vaccine hesitancy, as well as their attitudes toward the intervention. The study was completed with 61 participants. After participation in the simulation, pretest/posttest data showed a mean increase in participants' knowledge of the measles, mumps, and rubella vaccine. There was a significant improvement in the test scores from 62.62 ± 14.82 to 69.50 ± 15.75; z = -3, 897 (1-17 days) (p = 0.001). A postintervention questionnaire revealed participants most appreciated the direct interaction with a live person, the opportunity to observe classmates' performance and share feedback, multistage structure, and safety. Drawbacks included stress from being observed by peers, time constraints, and the necessity of sharing the nursing role with a partner during the scenario. Another drawback is the simulation's inability to effectively prepare participants for hesitancy in clinical settings as they needed to assess natural clinical settings. Simulations incorporating vaccine hesitancy education and standardized patients can effectively prepare nursing students for situations related to vaccine hesitancy in community clinical settings.

2024-11-26·Blood Advances

Magrolimab plus rituximab with or without chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma

Article

作者: Huo, Yanan ; Hacohen-Kleiman, Gal ; Collins, Graham P. ; Smith, Sonali M. ; Asch, Adam ; Ku, Matthew ; Zhang, Yi ; Renard, Camille ; Maakaron, Joseph E. ; Advani, Ranjana ; Mehta, Amitkumar ; Popplewell, Leslie ; Keane, Colm ; Roschewski, Mark ; Flinn, Ian W. ; Ghosh, Nilanjan

AbstractPatients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) ineligible for available salvage therapies have limited options for long-term disease control, necessitating novel treatments. Previously, magrolimab (anti–cluster-of-differentiation-47 antibody) plus rituximab (M+R) demonstrated ability to induce complete responses (CR) in R/R DLBCL. Here, we report 3-year follow-up data from this phase 1b/2 study assessing long-term safety and efficacy of M+R, and initial safety and efficacy of M+R plus gemcitabine-oxaliplatin (M+R-GemOx), in R/R DLBCL. After magrolimab priming, 4 groups of patients received M+R, 10 to 45 mg/kg magrolimab with 375 mg/m2 rituximab; patients receiving M+R-GemOx received 30 or 45 mg/kg magrolimab with 375 mg/m2 rituximab, 1000 mg/m2 gemcitabine, and 100 mg/m2 oxaliplatin. Primary end points were treatment-emergent adverse events (TEAEs) and objective response rate (ORR). Secondary end points included duration of response (DOR), progression-free survival (PFS), and overall survival (OS). Of 132 patients treated, 99 received M+R and 33 received M+R-GemOx. Most common any-grade TEAEs were fatigue (M+R, 40%; M+R-GemOx, 70%), infusion-related reactions (M+R, 39%), or anemia (M+R-GemOx, 70%). Treatment-related TEAEs led to magrolimab discontinuation in 7% (M+R) and 6% (M+R-GemOx). One death was considered treatment related (M+R-GemOx, colitis). M+R ORR was 24% (CR, 12%), and median DOR was 9.3 months. Median PFS and OS were 1.8 and 9.2 months, respectively. M+R-GemOx ORR was 52% (CR, 39%); 12-month DOR rate was 66.6% (95% confidence interval, 33.1-86.1). Median PFS and OS were 3.9 months and not reached, respectively. These results demonstrate that M+R with/without GemOx is well tolerated, and M+R-GemOx has clinical activity in patients with R/R DLBCL. This trial was registered at www.clinicaltrials.gov as #NCT02953509.

2024-11-26·Blood Advances

Magrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trial

Article

作者: Ghosh, Nilanjan ; Su-Feher, Linda ; Renard, Camille ; Hacohen-Kleiman, Gal ; Roschewski, Mark ; Advani, Ranjana ; Collins, Graham P. ; Flinn, Ian W. ; Smith, Sonali M. ; Huo, Yanan ; Mehta, Amitkumar ; Bartlett, Nancy L. ; Popplewell, Leslie

AbstractRelapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) is generally considered incurable with current treatment options. Previous phase 1b/2 results showed combining magrolimab (anti–cluster-of-differentiation [CD] 47 antibody) with the anti-CD20 antibody rituximab (M+R) has antitumor activity against R/R iNHL. We report 3-year follow-up data from this phase 1b/2 study assessing long-term safety and efficacy of M+R in R/R iNHL. After magrolimab priming, 4 patient groups in phase 1b M+R received 10 to 45-mg/kg magrolimab doses with 375 mg/m2 rituximab. Phase 2 explored 30 and 45 mg/kg magrolimab. Primary end points were treatment-emergent adverse events (TEAEs) and objective response rate (ORR). Secondary end points included duration of response (DOR), progression-free survival (PFS), and overall survival (OS). Exploratory analysis included circulating tumor DNA, biomarkers of magrolimab tumor penetration, and drug target expression assessments. Of 46 patients treated in phase 1b/2, 42 had follicular lymphoma and 4 had marginal zone lymphoma. All patients experienced ≥1 any-grade TEAE, and 44 reported ≥1 treatment-related TEAE. No additional toxicities were reported during long-term follow-up, and there were no treatment-related deaths. Median follow-up was 36.7 (range, 1.2-62.3) months. The ORR was 52.2%, with 30.4% achieving a complete response. The median DOR was 15.9 months, and median time-to-response was 1.8 months. Median PFS and OS were 7.4 (95% confidence interval, 4.8-13.0) months and not reached, respectively. These results demonstrate the long-term safety and efficacy of M+R in patients with iNHL and support further exploration of CD47-based treatment combinations. This trial was registered at www.ClinicalTrials.gov as #NCT02953509.

10

项与 Measles, mumps and rubella vaccine(Merck Sharp & Dohme) 相关的新闻（医药）

2024-04-05

·Pharmaceutical Technology

England’s MMR vaccinations up 23% following NHS initiative

Vaccinations were up four fold in those aged five to 25 years old. Image credit: Shutterstock/didesign021. England’s NHS is calling its recent campaign to boost vaccination rates a success amidst a surge in measles, mumps , and rubella (MMR) cases. Latest data released by the health service shows that there were 23% more vaccinations in the first quarter of 2024 compared to the same time last year. A total of 360,964 jabs were delivered between January and March this year, compared to 293,847 in 2023. The biggest jump was seen in those aged five to 25 years old, with vaccinations up four-fold in that group between 2024 and 2023. In January, the UK Health Security Agency (UKHSA) declared a national incident following a surge in measles outbreaks across Britain. The highly contagious measles virus can cause serious illness and, in some cases, even death, in children and adults. It is also dangerous if caught during pregnancy, potentially resulting in stillbirth, miscarriage, and low birth weight. In the same month, the NHS started contacting millions of patients and carers in England to book their children in for a catch-up vaccine with a GP. The campaign also targeted those in the 11 to 25 year-age group in areas with low vaccine uptake rates such as London and the West Midlands. See Also: Touchlight joins forces with University of Liverpool for NSCLC vaccine Zoetis gets grant for recombinant viral vectors for multivalent pathogen protection in vaccines At the time, the NHS said its figures indicated that more than 3.4 million children under 16 years of age were unprotected against the three infectious diseases. There have been 934 confirmed cases of measles in England since the beginning of October last year, according to data from the UKSHA. The West Midlands accounted for around half of the cases seen since January. UKSHA head of immunisation Dr Mary Ramsay said: “The big increase in people, especially children, getting their MMR vaccine following our recent marketing campaign on missed immunisations is fantastic to see.” The NHS uses MSD’s M-M-RVaxPro and GSK ’s Priorix for MMR vaccines. The shots were approved for use in the UK in 1997 and 2006, respectively. They are recommended for all babies and young children, with adults able to receive one if unvaccinated. Two doses of the vaccines are required, resulting in lifelong protection with high efficacy against the three viruses which are easily spread between unvaccinated people. The World Health Organization (WHO) has said 95% vaccine coverage would eliminate measles in a population completely. The US has also seen a surge in measles cases , with the Centers for Disease Control and Prevention (CDC) reporting 97 cases in 2024 so far. Over half of the patients diagnosed with the virus were hospitalised. The CDC issued a health alert urging travellers, especially children, to get vaccinated. A statement from the American Medical Association echoed the call for vaccinations. The US also uses MSD’s M-M-R II and GSK’s Priorix.

疫苗上市批准

2024-03-21

·GlobeNewswire-Health Care

Rate of national measles cases highlights importance of vaccination

JEFFERSON CITY, Mo., March 21, 2024 (GLOBE NEWSWIRE) -- As vaccine uptake continues to decrease, measles cases or outbreaks have emerged in several states, including Missouri earlier this year. Nationally, the total number of measles cases has already reached the level that occurred during the entire year of 2023. With cases reported across the country, the Missouri Department of Health & Senior Services (DHSS) recommends parents and guardians check their child’s vaccination records to make sure they have received the measles, mumps and rubella (MMR) vaccine. This vaccine has been used in the United States since the 1970s and is a safe and effective way to protect children from measles. To be fully immunized, children are recommended to receive two doses of the MMR vaccine, with the first dose between ages 12-15 months and the second dose between ages 4-6 years old. Infants as young as 6 months can receive the first dose if traveling to areas where the measles infection rate is high. Families should consult their health care provider to discuss appropriate vaccine options for their children. Herd immunity, achieved through a measles vaccination rate of 95% or more, is crucial for preventing disease outbreaks in the community and protecting vulnerable populations who cannot receive vaccines. “Achieving this level of vaccination creates a barrier that limits the spread of infectious disease within a community, safeguarding those who are unable to be vaccinated due to their age or compromised immune systems,” said Dr. George Turabelidze, state epidemiologist with DHSS. Statewide, the MMR vaccination rate among kindergarteners has dropped steadily from 95.4% in the 2016-2017 school year to 90.5% at the start of the 2023-2024 school year, according to preliminary data reported by Missouri school districts. Religious (non-medical) exemptions have simultaneously increased from 1.9% to 3.5%. The measles vaccine, given as part of the MMR (measles, mumps and rubella) vaccine, is extremely effective, giving those vaccinated with just one dose 93% protection against measles infection. Both doses of the vaccine provide individuals with a 97% protection rate throughout their lifetime. Measles is a highly contagious and serious disease, especially serious for children under age five and those who are immunocompromised. Common symptoms include a rash that starts as flat red spots on the head and spreads to other parts of the body, high fever, cough, runny nose, red and watery eyes, and tiny white spots inside the mouth. But in some instances, individuals with measles will develop brain infection, which can lead to brain damage, and for some, the disease is fatal even with the best care. The virus spreads through coughing and sneezing and can live for up to two hours in an airspace after an infected person leaves an area. A person can spread measles without knowing they are infected. If not treated, complications can grow in severity. Most health insurance plans cover vaccines, but individuals should check with their insurance provider to verify coverage. For those without insurance, the Vaccines for Children Program, funded by the Centers for Disease Control and Prevention (CDC), provides free vaccines to children who qualify. Additionally, most local public health agencies throughout the state of Missouri offer vaccinations at affordable rates. To find a local public health agency near you and schedule an appointment, visit the Local Public Health Agency Directory. Mission of the Missouri Department of Health and Senior Services (DHSS): To promote health and safety through prevention, collaboration, education, innovation and response. MEDIA CONTACT:Lisa Cox (573-751-6062)Missouri Department of Health and Senior ServicesMedia Inquiry Form

疫苗

2024-02-01

·医药魔方

默沙东2023年财报：K药250亿美元登顶“药王”宝座，HPV疫苗近90亿美元

2月1日，默沙东公布2023年业绩，全年营收601.15亿美元，同比增长1%，扣除新冠口服药Lagevrio（莫诺拉韦）影响后，同比增长9%。默沙东制药业务收入535.83亿美元，同比增长3%，其中，中国区收入67.1亿美元，占据默沙东全球市场12.5%的份额，同比增长32%。王牌品种Keytruda（帕博利珠单抗）迎来其历史性高光时刻，全年营收250.11亿美元，同比增长19%，荣登2023年“药王”宝座。主要得益于在全球早期癌症患者群体（包括TNBC和RCC）中的使用，以及在全球转移性癌症患者中持续的强劲需求。九价HPV疫苗Gardasil/Gardasil 9销售额达88.86亿美元（+29%）。这两款产品占据默沙东总收入的56.4%，也成就了默沙东在肿瘤和疫苗领域的行业领导者地位。肿瘤领域产品Welireg（HIF-2α抑制剂）和Reblozyl（罗特西普），抗巨细胞病毒感染药物Prevymis（来特莫韦），以及15价肺炎球菌疫苗Vaxneuvance（V114）的销售额均呈现双位数及以上增长，带来了可观的增量收入。2023年默沙东主要产品销售额（亿美元）Keytruda无疑是默沙东的荣耀，自上市以来在与O药的缠斗中，已经将对手远远甩在身后。与此同时，这款超级重磅药物也面临2028年专利悬崖危机。不过在今年的JPM大会上，默沙东首席执行官Rob Davis向外界传达了乐观的信号，他表示，“现阶段讨论的焦点无疑是Keytruda和2028，不过我们越来越不再关注2028年，这只是一个年份而已。”Rob Davis拥有如此底气也不足为奇，毕竟默沙东已经针对这一即将面临的挑战未雨绸缪，做出了充分的应对措施。2023年，默沙东针对Keytruda新开了多项联合治疗III期临床研究，其中包括与肿瘤mRNA疫苗V940（mRNA-4157）联合治疗非小细胞肺癌（NSCLC）的两项研究，以及与TROP2 ADC新药MK-2870（从科伦博泰引进）联合一线治疗NSCLC的关键III期研究。除了继续挖掘Keytruda与其他疗法联合的治疗潜力，默沙东还计划通过增补肿瘤产品管线进一步丰富产品群来应对肿瘤业务可能面临的收入下滑情况。LSD1抑制剂Bomedemstat、BTK抑制剂Nemtabrutinib以及CYP11A1抑制剂MK-5684均被推向了III期临床。另外，去年10月，默沙东还以高达220亿美元的总金额引进了第一三共3款ADC新药 patritumab deruxtecan（HER3-DXd）、ifinatamab deruxtecan（I-DXd）和raludotatug deruxtecan（R-DXd），其中patritumab deruxtecan上市申请已于2023年12月获得FDA优先审评，适应症为三线治疗EGFR突变NSCLC。今年，受益于ADC候选药物以及癌症疫苗，默沙东将其肿瘤学组合下一个十年预估值提升到了200亿美元以上。疫苗领域，宫颈癌疫苗Gardasil/ Gardasil 9贡献了最核心的份额，同比增长29%至88.86亿美元，这主要仍得益于中国市场的强劲需求。用于预防麻疹、腮腺炎或水痘的ProQuad/M-M-R II/Varivax系列疫苗的销售额稳健增长达到23.68亿美元，另一种针对婴幼儿轮状病毒感染疫苗RotaTeq的销售额为7.69亿美元。默沙东和辉瑞在肺炎球菌疫苗赛道上开展了一场持久拉锯战。2023年，23价肺炎球菌疫苗Pneumovax 23销售额持续大幅下滑仅为4.12亿美元，跌幅达32%，也是默沙东财报中销售额下跌最严重的产品之一。而辉瑞Prevnar系列产品2023年卖出了64.4亿美元的好成绩。不过，默沙东在肺炎球菌疫苗赛道仍然有赶超辉瑞之势，15价肺炎球菌疫苗Vaxneuvance（V114）已于2021年7月获批上市，2022年8月将适用人群覆盖至6周龄以上儿童，2023年的销售额是2022年的近4倍，已达到6.65亿美元；用于成人的21价肺炎球菌疫苗V116对标Prevnar 20，已于2023年12月向FDA递交了上市申请并被纳入优先审评，如果获得上市批准，V116将成为首个专为成人设计的肺炎球菌结合疫苗。此外，默沙东布局在心血管/代谢、神经和免疫疾病领域都有产品布局，每一个细分赛道中都有新生代产品即将进入收获期或进入后期开发阶段，有望进一步补强现有产品群。在Adempas（2.55亿美元，+7%）的基础上，肺动脉高压新药Sotatercept蓄势待发，其生物制品许可申请（BLA）已获FDA授予优先审评资格，PDUFA日期定为2024年3月26日。代谢领域两款治疗2型糖尿病的产品Januvia与Janumet市场份额进一步萎缩。不过，其在研GLP-1R/GCGR双靶点激动剂efinopegdutide用于治疗非酒精性脂肪性肝炎 (NASH)的IIa期临床研究已于去年6月公布了积极结果。刚过去的JPM大会上，Robert Davis表示正在寻求具有减肥以外益处的GLP-1靶向疗法，因为非减肥适应症的开发更容易获得报销。心血管领域，口服PCSK9抑制剂MK-0616被寄予厚望，去年8月，默沙东新开了MK-0616治疗成人高胆固醇血症的大型III期CORALreef研究，该项目将在三项全球性研究中招募约17000名受试者，研究结果颇受期待。2023年，默沙东研发投入高达305.31亿美元，相当于将2023年收入的一半用于研发，其中仅收购与剥离造成的相关成本高达81.9亿美元。而其2022年的研发投入仅为135.48亿美元。仅在2023年，默沙东共启动了20多个III期研究项目。其中包括8款新的资产首次于2023年进入III期阶段。足以看出其在新药研发过程中重金投入的魄力。默沙东表示，今年计划开展更多临床试验。与此同时，Rob Davis表示，该公司正在寻找更多的中型交易。默沙东也对2024年业绩做了展望，预计全年收入将达到626-642亿美元。推荐阅读强生2023年财报出炉！乌司奴单抗超108亿美元，达雷妥尤单抗逼近百亿美元赛诺菲2023年财报：度普利尤单抗117亿美元，已在中美欧申报COPD适应症罗氏2023年财报：眼科双抗上市两年突破26亿美元，中国区收入60亿美元诺和诺德2023年财报：司美格鲁肽大卖212亿美元，Wegovy增长407%诺华2023年财报：Entresto销售额破60亿美元，中国区业绩增长17%GSK RSV疫苗销售额破十亿美元，继续领先辉瑞辉瑞2023年财报：营收585亿美元，RSV疫苗收入8.9亿美元翻倍增长！Enhertu 2023年全球销售25亿美元Copyright © 2024 PHARMCUBE. All Rights Reserved.欢迎转发分享及合理引用，引用时请在显要位置标明文章来源；如需转载，请给微信公众号后台留言或发送消息，并注明公众号名称及ID。免责申明：本微信文章中的信息仅供一般参考之用，不可直接作为决策内容，医药魔方不对任何主体因使用本文内容而导致的任何损失承担责任。

疫苗财报临床3期信使RNA优先审批

100 项与 Measles, mumps and rubella vaccine(Merck Sharp & Dohme) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	J07BD52	-

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
麻疹	美国	Merck & Co., Inc.	1971-04-22
腮腺炎	美国	Merck & Co., Inc.	1971-04-22
风疹	美国	Merck & Co., Inc.	1971-04-22

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04016714 (V114-026 \| PNEU-PED-EU-2, CTgov)	临床3期	肺炎球菌感染	1,191	VARIVAX™+Vaxelis™+V114+M-M-R®II (V114)	(艱蓋餘憲選築願窪鏇壓) = 鹹鏇醖遞齋齋蓋繭廠範簾顧遞餘築鹽獵艱簾醖 (襯鬱鑰窪壓鬱餘鏇築構, 鹹選醖壓衊積觸選醖製 ~ 積獵鏇鹹襯鬱衊醖鬱製) 更多	-	2022-12-01
				VARIVAX™+Vaxelis™+Prevenar 13™+M-M-R®II (Prevenar 13™)	(艱蓋餘憲選築願窪鏇壓) = 襯廠網廠鏇糧醖網襯壓簾顧遞餘築鹽獵艱簾醖 (襯鬱鑰窪壓鬱餘鏇築構, 蓋積齋顧壓鏇積蓋遞醖 ~ 餘壓衊獵繭獵憲選觸衊) 更多
NCT03893448 (PNEU-PED \| V114-029, CTgov)	临床3期	肺炎球菌感染 \| 肺炎 \| 18型肌张力障碍	1,720	HIBERIX™+Pentacel™+Varivax™+RECOMBIVAX HB™+VAQTA™+RotaTeq™+V114+MMR II™ (V114)	鹽廠鏇齋壓淵齋鹹憲窪(廠觸醖鹽築選構願窪築) = 選齋範醖遞鬱簾鹽繭憲醖鏇膚襯鹽簾膚遞積餘 (製獵餘醖醖餘遞選膚齋, 襯齋願選廠夢繭鏇遞淵 ~ 壓壓網網觸糧醖範觸顧) 更多	-	2022-03-25
				HIBERIX™+Pentacel™+Varivax™+RECOMBIVAX HB™+VAQTA™+RotaTeq™+Prevnar 13™+MMR II™ (Prevnar 13™)	鹽廠鏇齋壓淵齋鹹憲窪(廠觸醖鹽築選構願窪築) = 積構積餘衊鬱壓積鑰蓋醖鏇膚襯鹽簾膚遞積餘 (製獵餘醖醖餘遞選膚齋, 齋觸壓觸齋襯襯憲願觸 ~ 觸獵積網網網衊鬱鹹窪) 更多
NCT00148941 (CTgov)	临床3期	白喉 \| 百日咳 \| 破伤风	4,209	SB213503 lot 1+M-M-R II (SB213503 Lot 1 + M-M-R Group)	遞餘壓製鏇襯膚範衊艱(窪衊簾獵糧艱淵鬱願窪) = 構壓夢蓋遞觸衊製糧鹹簾壓膚夢廠衊願遞壓夢 (積網願獵夢獵艱窪蓋遞, 壓繭願淵積壓窪獵鹹範 ~ 憲獵繭憲壓廠衊構膚網) 更多	-	2020-02-05
				SB213503 lot 2+M-M-R II (SB213503 Lot 2 + M-M-R Group)	遞餘壓製鏇襯膚範衊艱(窪衊簾獵糧艱淵鬱願窪) = 膚鏇簾餘醖廠鏇鑰遞齋簾壓膚夢廠衊願遞壓夢 (積網願獵夢獵艱窪蓋遞, 醖遞夢餘鹹簾襯齋鬱醖 ~ 糧膚繭選製鹹選窪膚鬱) 更多
NCT03239873 (V210-A03, CTgov)	临床3期	水痘	600	VARIVAX PE34+M-M-R II (VARIVAX PE34 + M-M-R II)	醖繭鬱艱蓋顧繭觸淵願(顧糧積鹽製衊鬱構艱築) = 醖糧憲淵鏇夢鹽壓窪艱衊艱蓋窪積網獵願餘壓 (鏇齋廠淵積觸網鏇糧壓, 鹹艱積淵壓網醖獵顧鹽 ~ 製觸選鏇醖糧廠鏇鑰醖) 更多	-	2019-08-26
				M-M-R® II vaccine (VARIVAX (2016 CP) + M-M-R II)	醖繭鬱艱蓋顧繭觸淵願(顧糧積鹽製衊鬱構艱築) = 願觸築製窪襯夢襯選築衊艱蓋窪積網獵願餘壓 (鏇齋廠淵積觸網鏇糧壓, 壓積齋鏇製淵鑰鬱夢襯 ~ 夢網餘網構觸壓製糧繭) 更多
NCT01553279 (V419-011, CTgov)	临床3期	细菌感染 \| 脑膜炎 \| 病毒感染	284	Hib-MCC+V419+PREVNAR 13®+MCC-TT+MMR Vaccine (V419 and MCC-TT)	觸壓鹽醖糧蓋膚衊糧憲(鹽積鹹範襯窪顧糧範鏇) = 選獵選繭餘夢壓廠艱製遞襯艱壓鹹憲齋獵獵衊 (夢鹽簾網鏇網網鬱觸齋, 範鏇獵衊衊觸糧蓋繭網 ~ 觸壓鹹獵蓋憲顧鑰齋觸) 更多	-	2019-03-28
				Hib-MCC+MCC-CRM+V419+PREVNAR 13®+MMR Vaccine (V419 and MCC-CRM)	觸壓鹽醖糧蓋膚衊糧憲(鹽積鹹範襯窪顧糧範鏇) = 顧憲範鹹蓋願鏇齋淵鑰遞襯艱壓鹹憲齋獵獵衊 (夢鹽簾網鏇網網鬱觸齋, 窪蓋遞糧網窪鏇製鹽膚 ~ 製製範遞鏇窪鬱壓夢選) 更多
NCT02062502 (V210-063, CTgov)	临床3期	水痘	611	VARIVAX™ 2007 process+M-M-R II™	廠觸願艱獵襯鹹簾衊鹽(廠鹹積選餘糧艱鹽獵糧) = 築糧衊蓋襯範顧窪憲繭簾獵廠醖鹽餘範範遞遞 (壓壓餘範築簾糧遞願顧, 製蓋顧簾鑰襯齋窪觸淵 ~ 齋構廠選構鏇願鹽選襯) 更多	-	2016-03-01
NCT01000311 (CTgov)	临床3期	脑膜炎球菌感染	529	PCV+HBV+MenACWY-CRM+MMR (MenACWY-CRM + Routine Vaccines)	範艱積廠遞壓夢鏇廠壓(壓醖壓構襯鏇網襯構蓋) = 積廠獵壓膚淵襯繭製齋齋廠顧齋憲製網鑰簾簾 (夢衊製壓鑰遞廠願淵窪, 積築壓遞衊糧鑰艱積遞 ~ 膚衊構夢齋窪夢鏇衊鏇) 更多	-	2014-03-26
				PCV+HBV+MMR (Routine Vaccines)	範艱積廠遞壓夢鏇廠壓(壓醖壓構襯鏇網襯構蓋) = 鏇窪憲築簾壓遞製膚觸齋廠顧齋憲製網鑰簾簾 (夢衊製壓鑰遞廠願淵窪, 簾憲廠醖獵範範衊鏇選 ~ 獵艱鹽遞醖齋衊窪鏇蓋) 更多
NCT00289783 (CTgov)	临床3期	脑膜炎 \| 嗜血杆菌感染	4,441	GSK Biologicals' Haemophilus influenzae type b+Varivax+Prevnar+Pediarix+M-M-R II (Menhibrix A Group)	網網鬱糧繭蓋網願鑰窪(觸鹹襯顧積築憲襯夢簾) = 簾願簾鹽繭襯鏇糧醖壓鏇簾鹽構築鏇觸願觸餘 (範艱鹽廠觸鹽觸鑰膚鹽, 選製鹹鬱廠鹽顧艱壓構 ~ 襯淵獵顧構夢鏇遞構製) 更多	-	2012-08-06
				GSK Biologicals' Haemophilus influenzae type b+Varivax+Prevnar+Pediarix+M-M-R II (Menhibrix B Group)	網網鬱糧繭蓋網願鑰窪(觸鹹襯顧積築憲襯夢簾) = 願獵範膚範膚積糧蓋蓋鏇簾鹽構築鏇觸願觸餘 (範艱鹽廠觸鹽觸鑰膚鹽, 願艱醖簾遞窪網鹹鑰淵 ~ 糧鹹鏇構願夢顧鑰獵製) 更多
NCT00345683 (CTgov)	临床3期	脑膜炎 \| 嗜血杆菌感染	4,021	Neisseria meningitidis serogroups C+Varivax+Prevnar+M-M-R II (Menhibrix Group)	鬱鑰蓋淵鏇鏇積蓋淵艱(鬱願鏇獵壓襯網襯艱衊) = 積鑰醖簾積窪顧簾壓觸鹹網廠廠壓壓襯醖遞鹽 (製憲網鏇顧憲構鹹廠構, 繭襯遞鏇顧鬱蓋膚鏇糧 ~ 觸範鏇構簾範襯糧鹽願) 更多	-	2012-07-20
				PedvaxHIB+Varivax+Prevnar+M-M-R II (ActHIB Group)	鬱鑰蓋淵鏇鏇積蓋淵艱(鬱願鏇獵壓襯網襯艱衊) = 餘壓鹽簾築襯願選夢構鹹網廠廠壓壓襯醖遞鹽 (製憲網鏇顧憲構鹹廠構, 齋顧蓋淵淵襯衊鏇鏇範 ~ 醖衊築鹽選餘衊繭鑰鹽) 更多